February 5th 2021
By Tony Hagen
Celltrion aims to try a direct marketing approach in Canada to streamline sales of its subcutaneous form of Remsima.
January 28th 2021
In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.
January 27th 2021
The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.
January 25th 2021
It took Henlius years to get a rituximab biosimilar approved in China. Now, that process could be cut in half, owing to significant regulatory reforms.
January 18th 2021
Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.
January 15th 2021
CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.
January 14th 2021
By Deana Ferreri, PhD
A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.
January 7th 2021
Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.
January 6th 2021
Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.
January 4th 2021
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
